MF59: all 31 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older AdultsRecruitingNCT07838298Phase 4
• Influenza Vaccination Strategy for Patients With Hematologic MalignancyRecruitingNCT07485855Phase 3
• Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical TrialNot yet recruitingNCT07126652Not applicable
• Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian InfluenzaCompletedNCT03682120Phase 2Results posted
• Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59CompletedNCT03497845Phase 2Results posted
• Phase 3 Safety and Immunogenicity Study of aQIV in Elderly AdultsCompletedNCT03314662Phase 3Results posted
• Panblok H7 Vaccine Adjuvanted With AS03 or MF59CompletedNCT03283319Phase 2Results posted
• Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of AgeCompletedNCT02587221Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of AgeCompletedNCT01346592Phase 3Results posted
• Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly SubjectsCompletedNCT01162122Phase 3Results posted
• Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 MonthsCompletedNCT00996307Phase 2/3Results posted
• Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)CompletedNCT00973700Phase 3Results posted
• Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly AdultsCompletedNCT00973349Phase 2/3Results posted
• Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)CompletedNCT00972816Phase 2/3Results posted
• Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult SubjectsCompletedNCT00481065Phase 2Results posted
• Comparative Immunologic Mechanisms and Microbiome Interactions Following Different Influenza Vaccine Formulations in Older AdultsCompletedNCT07805837Phase 4
• Reducing the Burden of Influenza After Solid-Organ TransplantationCompletedNCT03699839Phase 2/3
• Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong KongCompletedNCT03330132Phase 4
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: ImmunologyCompletedNCT03014310Phase 1
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy AdultsCompletedNCT02624219Phase 1
• H7N9 Mix and Match With MF59 in Healthy Elderly PersonsCompletedNCT02213354Phase 2
• H7N9 Mix and Match With AS03 and MF59 in Healthy AdultsCompletedNCT01942265Phase 2
• H7N9 Mix and Match With MF59 in Healthy AdultsCompletedNCT01938742Phase 2
• H5N1 Mix and Match With MF59CompletedNCT01317745Phase 1
• Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer PatientsCompletedNCT01097096Phase 2
• Safety and Immunogenicity of A/H1N1v Vaccines in Healthy AdultsCompletedNCT00943358Phase 1
• Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59CompletedNCT00912496Phase 1
• Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in AdultsCompletedNCT00382187Phase 2
• gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent FemalesCompletedNCT00133497Phase 2
• Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory AdultsCompletedNCT00133471Phase 1/2
• A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult VolunteersCompletedNCT00000832Phase 1

← MF59 overview